---
schema_version: "secwatch.filing_event.v1"
accession: "0001798749-23-000005"
form_type: "8-K"
ticker: "JBIO"
cik: "0001798749"
company_name: "Jade Biosciences, Inc."
filed_at: "2023-01-23T23:59:59+00:00"
generated_at: "2026-06-20T11:55:47.710063+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Aerovate Therapeutics appoints Donald Santel to Board of Directors

## Summary
- Santel appointed as Class I director effective Jan 19, 2023; term expires at 2025 annual meeting.
- He joins the Nominating and Corporate Governance Committee; other committees unchanged.
- Santel brings over 40 years biopharma experience, including CoTherix and Hyperion (PAH focus) and Oyster Point Pharma.
- He will receive standard non-employee director equity and cash compensation for 2023.
- Board determined Santel is independent under Nasdaq listing standards.

## SEC filing metadata
- accession: 0001798749-23-000005
- form_type: 8-K
- ticker: JBIO
- cik: 0001798749
- company_name: Jade Biosciences, Inc.
- filed_at: 2023-01-23T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1798749/000179874923000005/0001798749-23-000005-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1798749/000179874923000005/tmb-20230119x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001798749-23-000005
- JSON: https://secwatch.observer/filing/0001798749-23-000005.json
- Plain text: https://secwatch.observer/filing/0001798749-23-000005.txt

## Key facts
- Executive change
  Donald J. Santel was appointed as Director at Jade Biosciences, Inc..
  - Action: appointed
  - Role: Director
  source text: Effective as of January 19, 2023 (the “Effective Date”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the “Board”) of Aerovate Therapeutics, Inc. (the “Company”), the Board appointed Donald J. Santel as a member of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1798749/000179874923000005/0001798749-23-000005-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.